Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2529 of 2529 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/09
End: 07/31/12
Due: 07/31/13
Phase: N/A
Priority: Normal
Start: 10/25/16
End: 10/22/18
Due: 10/22/19
Phase: N/A
Priority: Normal
Start: 05/31/03
End: 06/30/05
Due: 06/30/06
Phase: N/A
Priority: Normal
Start: 02/28/06
End: 07/31/13
Due: 07/31/14
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors | NCT00879905 | Novartis Pharmaceuticals | user2@example.com | None | 2009-05-31 | 2012-07-31 | 2013-07-31 | - | - | 2025-07-14 |
| Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes. | NCT02887183 | Novartis Pharmaceuticals | user2@example.com | None | 2016-10-25 | 2018-10-22 | 2019-10-22 | - | - | 2025-07-14 |
| A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion | NCT00238472 | Novartis Pharmaceuticals | user2@example.com | None | 2003-05-31 | 2005-06-30 | 2006-06-30 | - | - | 2025-07-14 |
| Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer | NCT00320710 | Novartis Pharmaceuticals | user2@example.com | None | 2006-02-28 | 2013-07-31 | 2014-07-31 | - | - | 2025-07-14 |